معرفی
Dr. Colin Petrie is an Honorary Senior Lecturer at the University of Glasgow, affiliated with the School of Cardiovascular & Metabolic Health. His research focuses on heart failure mechanisms, iron deficiency management in cardiac patients, and diabetes-cardiovascular comorbidities. He has contributed to major trials like the IRONMAN and SUGAR-DM-HF studies, evaluating therapies like ferric derisomaltose and empagliflozin. His work spans clinical trials, pharmacological interventions, and imaging biomarkers in cardiology.
Key research interests include:
- Pathophysiology of heart failure with reduced ejection fraction (HFrEF)
- Optimization of iron deficiency treatment in hospitalized vs. ambulatory patients
- Effects of SGLT2 inhibitors on renal and cardiac outcomes in diabetic cardiomyopathy
- Microvascular injury assessment in acute myocardial infarction
Recent publications highlight advancements in IV iron therapies (IRONMAN trial), empagliflozin's renal benefits in heart failure, and interventional cardiology outcomes from the T-TIME trial. His work bridges clinical practice and translational research in cardiovascular health.
Dr. Petrie collaborates on large-scale trials evaluating pharmacological agents and diagnostic strategies, contributing to evidence-based guidelines in cardiology.